Christopher T Veldkamp
age ~45
from Fort Atkinson, WI
- Also known as:
-
- Christopher Thomas Veldkamp
- Chirstopher T Veldkamp
- Chris Veldkamp
Christopher Veldkamp Phones & Addresses
- Fort Atkinson, WI
- Brule, WI
- Port Wing, WI
- Whitewater, WI
- 300 N 121St St #3, Milwaukee, WI 53226
- Hudsonville, MI
Resumes
Christopher Veldkamp
view sourceUs Patents
-
Engineered Cxcl12 Alpha Locked Dimer Polypeptide
view source -
US Patent:8524670, Sep 3, 2013
-
Filed:Nov 30, 2010
-
Appl. No.:12/956514
-
Inventors:Brian F. Volkman - Muskego WI, US
Christopher T. Veldkamp - Milwaukee WI, US
Francis C. Peterson - Racine WI, US
Thomas Sakmar - New York NY, US
Christoph H. Seibert - Frankfurt am Main, DE -
Assignee:Medical College of Wisconsin Research Foundation - Milwaukee WI
The Rockefeller University - New York NY -
International Classification:A61K 38/00
-
US Classification:514 193, 514 189, 514 196, 514 198, 514 11
-
Abstract:The present invention provides a novel CXCL12-αlocked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
-
Engineered Cxcl 12 Alpha Locked Dimer Polypeptide
view source -
US Patent:20090305984, Dec 10, 2009
-
Filed:Feb 26, 2009
-
Appl. No.:12/380308
-
Inventors:Brian F. Volkman - Muskego WI, US
Christopher T. Veldkamp - Milwaukee WI, US
Francis C. Peterson - Racine WI, US
Thomas Sakmar - New York NY, US
Christoph H. Seibert - Frankfurt am Main, DE -
Assignee:Medical College of Wisconsin Research Foundation - Milwaukee WI
-
International Classification:A61K 38/17
C07K 14/435 -
US Classification:514 12, 530324
-
Abstract:The present invention provides a novel CXCL12-αlocked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
-
Engineered Cxcl12 Alpha Locked Dimer Polypeptide
view source -
US Patent:20130316944, Nov 28, 2013
-
Filed:Jul 8, 2013
-
Appl. No.:13/936650
-
Inventors:Brian F. Volkman - Muskego WI, US
Christopher T. Veldkamp - Milwaukee WI, US
Francis C. Peterson - Racine WI, US
Thomas Sakmar - New York NY, US
Christoph H. Seibert - Frankfurt am Main, DE -
Assignee:The Rockefeller University - New York NY
Medical College of Wisconsin Research Foundation - Milwaukee WI -
International Classification:C07K 14/52
-
US Classification:514 38
-
Abstract:The present invention provides a novel CXCL12-αlocked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
-
Monomeric Cxcl121 Peptide And Use Thereof
view source -
US Patent:20200353045, Nov 12, 2020
-
Filed:Jan 17, 2020
-
Appl. No.:16/745809
-
Inventors:- Milwaukee WI, US
Joshua Ziarek - Boston MA, US
Christopher Veldkamp - Milwaukee WI, US
Francis Peterson - Racine WI, US -
Assignee:The Medical College of Wisconsin, Inc. - Milwaukee WI
-
International Classification:A61K 38/19
C07K 14/52 -
Abstract:The present invention provides a CXCL12peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
-
Monomeric Cxcl121 Peptide And Use Thereof
view source -
US Patent:20180148490, May 31, 2018
-
Filed:Jan 18, 2018
-
Appl. No.:15/874476
-
Inventors:- Milwaukee WI, US
Joshua Ziarek - Boston MA, US
Christopher Veldkamp - Milwaukee WI, US
Francis Peterson - Racine WI, US -
International Classification:C07K 14/52
A61K 38/00 -
Abstract:The present invention provides a CXCL12peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
-
Monomeric Cxcl121 Peptide And Methods Of Synthesis And Use Thereof
view source -
US Patent:20150361152, Dec 17, 2015
-
Filed:Jun 11, 2015
-
Appl. No.:14/736535
-
Inventors:- Milwaukee WI, US
Joshua Ziarek - Boston MA, US
Christopher Veldkamp - Milwaukee WI, US
Francis Peterson - Racine WI, US -
International Classification:C07K 14/52
-
Abstract:The present invention provides a CXCL12peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
Get Report for Christopher T Veldkamp from Fort Atkinson, WI, age ~45